Related Experiment Video

Updated: Jun 14, 2025

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
08:35

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

3.1K

Mendelian randomization study of sodium-glucose cotransporter 2 inhibitors in cardiac and renal diseases

Lei Chen1, Yongdi Zuo1, Manrong He1

  • 1Department of Nephrology, West China Hospital, Sichuan University, Chengdu, Sichuan, China.

The Journal of International Medical Research
|August 31, 2024
PubMed
Abstract

Insights

Sodium-glucose cotransporter 2 inhibitors (SGLT2i) show protective effects against specific kidney diseases like nephrotic syndrome and chronic glomerulonephritis. Further research is needed to confirm their efficacy and safety in cardiac and renal conditions.

Area of Science:

  • Nephrology
  • Cardiology
  • Pharmacology

Background:

  • Sodium-glucose cotransporter 2 inhibitors (SGLT2i) reduce blood sugar by inhibiting glucose and sodium reabsorption in kidney tubules.
  • Clinical trials on SGLT2i efficacy and safety for cardiac and renal diseases show inconsistent results.
  • Investigating SGLT2i's causal effects on specific renal and cardiac conditions is crucial.

Purpose of the Study:

  • To determine the causal effects of SGLT2i on various cardiac and renal diseases using Mendelian randomization.
  • To assess the impact of SGLT2i on potential adverse events.
  • To provide evidence for SGLT2i's role in managing kidney and heart conditions.

Main Methods:

  • Utilized Mendelian randomization analysis with single nucleotide polymorphisms from genome-wide association studies.
  • Selected urinary sodium as a downstream biomarker for SGLT2i activity.
  • Performed inverse variance weighted analysis, sensitivity analyses, and pleiotropy tests.

Main Results:

  • SGLT2i demonstrated a significant protective effect against nephrotic syndrome, chronic glomerulonephritis, and hypertensive nephropathy.
  • No causal effects were found between SGLT2i and cardiac diseases.
  • No causal effects were identified between SGLT2i and adverse events.

Conclusions:

  • SGLT2i act as protective agents for nephrotic syndrome, chronic glomerulonephritis, and hypertensive nephropathy.
  • The findings support the use of SGLT2i in managing specific kidney diseases.
  • SGLT2i do not appear to have causal effects on cardiac diseases or adverse events based on this analysis.
Keywords:
Mendelian randomizationSodium–glucose cotransporter 2 inhibitorcardiac diseasecausal effectchronic kidney diseasedrug target

More Related Videos

Transcutaneous Assessment of Renal Function in Conscious Rodents07:18

Transcutaneous Assessment of Renal Function in Conscious Rodents

Published on: March 26, 2016

12.4K
Evaluation of Vascular Control Mechanisms Utilizing Video Microscopy of Isolated Resistance Arteries of Rats10:28

Evaluation of Vascular Control Mechanisms Utilizing Video Microscopy of Isolated Resistance Arteries of Rats

Published on: December 5, 2017

9.3K

Related Concept Videos

Secondary Active Transport01:55

Secondary Active Transport

One example of how cells use the energy contained in electrochemical gradients is demonstrated by glucose transport into cells. The ion vital to this process is sodium (Na+), which is typically present in higher concentrations extracellularly than in the cytosol. Such a concentration difference is due, in part, to the action of an enzyme “pump” embedded in the cellular membrane that actively expels Na+ from a cell. Importantly, as this pump contributes to the high concentration of...
118.5K
Glucose Transporters01:27

Glucose Transporters

Glucose transporters facilitate the transport of glucose across the cell membrane. In addition to glucose, some glucose transporters can also aid the movement of other hexoses such as fructose, mannose, and galactose.
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
22.6K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
404
Glucose Absorption Into the Small Intestine01:26

Glucose Absorption Into the Small Intestine

Complex carbohydrates consumed cannot be absorbed into the small intestine in their original form. First, they must be hydrolyzed to a monosaccharide form such as glucose or galactose. These monosaccharides are then transported across the intestinal membrane and into the blood via transcellular transport. The intestinal epithelial cells allow the movement of these monosaccharides with a defined 'entry' through membrane transporter proteins present on their apical membrane and...
31.5K
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
183
Antihypertensive Drugs: Potassium-Sparing Diuretics01:28

Antihypertensive Drugs: Potassium-Sparing Diuretics

Liddle syndrome is a genetically inherited form of hypertension characterized by the overactivity of epithelial sodium channels in the nephron, the functional unit of the kidney. This heightened activity leads to increased sodium reabsorption and excessive excretion of potassium. To counteract this, potassium-sparing diuretics such as amiloride are used. They function by blocking these sodium channels, thereby reducing the influx of sodium into the epithelial cells and minimizing the loss of...
476